AGN 229666

Drug Profile

AGN 229666

Alternative Names: AGN-229666

Latest Information Update: 28 Jul 2016

Price : $50

At a glance

  • Originator Allergan
  • Class Eye disorder therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Allergic conjunctivitis

Most Recent Events

  • 27 Jul 2016 No development reported - Phase-III for Allergic conjunctivitis (Prevention) in Japan (Ophthalmic)
  • 27 Jul 2016 No development reported - Phase-III for Allergic conjunctivitis in Japan (Ophthalmic)
  • 01 Dec 2014 Allergan completes a phase III trial in Allergic conjunctivitis in Japan (NCT02161146)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top